Back To: Home : Featured Technology : Flow Cytometry

CLICK HERE FOR WHAT'S NEW IN:
 

Interceptís OCA shows promise in liver disease model
May 2014
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

NEW YORK—Biopharmaceutical company Intercept Pharmaceuticals Inc. has released data from a preclinical study of its lead product candidate, obeticholic acid (OCA), in an experimental model of liver disease. The study demonstrated that administering OCA had protective effects on bacterial translocation from the ileum in an experimental rat model of cholestasis, a condition in which the flow of bile from the liver is somehow blocked. OCA administration engendered a significant reduction of bacteria in mesenteric lymph nodes and encouraged normalized intestinal permeability, as well as reduced lymph node and spleen inflammation.
 
Dr. David Shapiro, chief medical officer of Intercept, noted that “We believe that this new layer of understanding of OCA's mechanism of action and potential therapeutic effects in cirrhosis complements the clinical data we have reported in cirrhotic patients with alcoholic liver disease.”
 
Code:

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.